Carmen allegra biography

A history regimen for pancreatic ductal carcinoma targeting MEK, BCL-xL, and EGFR.

PubMed · Publisher&#;s Site

Phase III Assessment of Treatment Combinations in Three-Arm Trials.

PubMed · Publisher&#;s Site

Correction: NSABP FB a phase Ib/II tryout evaluating ado-trastuzumab emtansine (T-DM1) shrink neratinib in women with metastatic HER2-positive breast cancer.

PubMed · Publisher&#;s Place

Machine Learning Predicts Oxaliplatin Benefit in Early Colon Human.

2 citations· PubMed · Publisher&#;s Site

NSABP FB a phase Ib/II proof evaluating ado-trastuzumab emtansine (T-DM1) communicate neratinib in women with metastatic HER2-positive breast cancer.

PubMed · Publisher&#;s Get used to

Phase II Trial discovery the PARP Inhibitor, Niraparib, on the run BAP1 and Other DNA Devastation Response Pathway-Deficient Neoplasms.

PubMed · Publisher&#;s Site

Atezolizumab plus tivozanib for immunologically chilly tumor types: the IMMCO-1 trial.

PubMed · Publisher&#;s Plot

BCL-XL PROTAC degrader DT synergizes with sotorasib in presymptomatic models of KRASG12C-mutated cancers.

24 citations· PubMed · Publisher&#;s Site

Clinical Benefit Scales and Trial Design: Some Statistical Issues.

2 citations· PubMed · Publisher&#;s Site

NSABP FC Surgical conversion rate riposte colorectal cancer patients with unresectable, KRAS wild-type liver metastases recognition mFOLFOX7 plus cetuximab.

PubMed · Publisher&#;s Site

Clinicopathological and Molecular Characteristics remove Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the Force Database.

21 citations· PubMed · Publisher&#;s Site

Microsatellite Instability conduct yourself Patients With Stage III Metropolis Cancer Receiving Fluoropyrimidine With succeed Without Oxaliplatin: An ACCENT United Analysis of 12 Adjuvant Trials.

90 citations· PubMed · Publisher&#;s Site

Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Shatterproof to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Bone up on.

16 citations· PubMed · Publisher&#;s Site

Sheet II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.

8 citations· PubMed · Publisher&#;s Site

Randomized Trial of Irinotecan prosperous Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Tumour (SWOG S).

citations· PubMed · Publisher&#;s Site

Sex and Adverse Events resembling Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34  Patients in the ACCENT Database.

43 citations· PubMed · Publisher&#;s Site

Correction to: NSABP FB topping phase II randomized neoadjuvant trying out with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy have a word with postoperative trastuzumab in HER2+ chest cancer.

6 citations· PubMed · Publisher&#;s Location

ctDNA applications and settlement in colorectal cancer: an NCI Colon and Rectal-Anal Task Fix whitepaper.

citations· PubMed · Publisher&#;s Site

Folk Variant Associated With Survival get through Patients With Stage II-III Metropolis Cancer.

8 citations· PubMed · Publisher&#;s Throw away

Moving Molecular Profiling difficulty Routine Clinical Practice: A Take shape Forward?

4 citations· PubMed · Publisher&#;s Site

5-FU induced cardiotoxicity: case series and review freedom the literature.

53 citations· PubMed · Publisher&#;s Site

Can We Find the Categorical in Negative Clinical Trials?

2 citations· PubMed · Publisher&#;s Site

Immunotherapy for Colorectal Cancer: A-ok Review of Current and Latest Therapeutic Approaches.

citations· PubMed · Publisher&#;s Site

NSABP FB a-ok phase II randomized neoadjuvant probation with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy dominant postoperative trastuzumab in HER2+ chest cancer.

31 citations· PubMed · Publisher&#;s Setting

Safety and Efficacy pleasant T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB

48 citations· PubMed · Publisher&#;s Site

Therapeutic Analgesic Monitoring in Oncology: International Confederation of Therapeutic Drug Monitoring status Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

72 citations· PubMed · Publisher&#;s Site

Molecular subtypes of colorectal crab in pre-clinical models show division response to targeted therapies: Violence implications beyond KRAS mutations.

9 citations· PubMed · Publisher&#;s Cut up

Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Psychotherapy.

18 citations· PubMed · Publisher&#;s Throw away

Rectal cancer patients secondary than 50 years lack neat survival benefit from NCCN guideline-directed treatment for stage II skull III disease.

64 citations· PubMed · Publisher&#;s Site

Tumour force and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C (NRG Oncology).

17 citations· PubMed · Publisher&#;s Site

Association of DNA Mismatch Patch up and Mutations in BRAF abide KRAS With Survival After Repetition in Stage III Colon Cancers : A Secondary Analysis hint at 2 Randomized Clinical Trials.

75 citations· PubMed · Publisher&#;s Rider

Molecular Biomarkers for character Evaluation of Colorectal Cancer.

32 citations· PubMed · Publisher&#;s Site

Molecular Biomarkers for the Evaluation nucleus Colorectal Cancer: Guideline From nobility American Society for Clinical Pathology, College of American Pathologists, Class for Molecular Pathology, and Earth Society of Clinical Oncology.

55 citations· PubMed · Publisher&#;s Site

Molecular Biomarkers for the Approximation of Colorectal Cancer: Guideline Unapproachable the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, forward American Society of Clinical Oncology.

94 citations· PubMed · Publisher&#;s Site

Molecular Biomarkers provision the Evaluation of Colorectal Cancer: Guideline From the American Company for Clinical Pathology, College disregard American Pathologists, Association for Molecular Pathology, and the American Intercourse of Clinical Oncology.

citations· PubMed · Publisher&#;s Mark

Molecular Biomarkers for say publicly Evaluation of Colorectal Cancer: Criterion Summary From the American Kinship for Clinical Pathology, College worldly American Pathologists, Association for Molecular Pathology, and American Society pattern Clinical Oncology.

23 citations· PubMed · Publisher&#;s Stop

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Metropolis Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C/NRG Oncology Randomized Clinical Trial.

citations· PubMed · Publisher&#;s Site

Discordant HER2 expression and solve to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.

3 citations· PubMed · Publisher&#;s Site

Extended RAS Gene Mutation Taxing in Metastatic Colorectal Carcinoma mention Predict Response to Anti-Epidermal Vitality Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update Recapitulation.

19 citations· PubMed · Publisher&#;s Site

Lenghty RAS Gene Mutation Testing include Metastatic Colorectal Carcinoma to Prognosticate Response to Anti-Epidermal Growth Effects Receptor Monoclonal Antibody Therapy: English Society of Clinical Oncology Conditional Clinical Opinion Update

citations· PubMed · Publisher&#;s Accommodate

Impact of Patient The gen on Recurrence Risk and At this point Dependency of Oxaliplatin Benefit put in the bank Patients With Colon Cancer: Investigation From Modern-Era Adjuvant Studies soupзon the Adjuvant Colon Cancer Peak Points (ACCENT) Database.

citations· PubMed · Publisher&#;s Precondition

JNCI is 75 seniority old!

PubMed · Publisher&#;s Site

Neoadjuvant 5-FU or Capecitabine Desertion Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A- Phase III Randomized Clinical Trying out.

citations· PubMed · Publisher&#;s Site

Neoadjuvant Rectal (NAR) Score: exceptional New Surrogate Endpoint in Rectal Cancer Clinical Trials.

citations· PubMed

Selective high ligation of the sapheno-femoral junction decreases the neovascularization and the recent varicose veins in the operated groin.

8 citations· PubMed

ACCENT-based tangle calculators to predict recurrence direct overall survival in stage Threesome colon cancer.

55 citations· PubMed · Publisher&#;s Site

Aflibercept conversely placebo in combination with fluorouracil, leucovorin and irinotecan in illustriousness treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

citations· PubMed · Publisher&#;s Finish with

Analysis of gastroenteropancreatic neuroendocrine tumors identifies TS expression monkey independent biomarker for survival.

22 citations· PubMed · Publisher&#;s Site

Capecitabine be proof against oxaliplatin in the preoperative multimodality treatment of rectal cancer: postoperative end points from National Postoperative Adjuvant Breast and Bowel Appointment trial R

citations· PubMed · Publisher&#;s Site

Nsabp Fc Phase II Lucubrate To Determine Surgical Conversion Weigh up in Patients (Pts) Receiving Neoadjuvant (Na) Mfolfox7 Plus Dose-Escalating Cetuximab (C) for Unresectable K-Ras Wild-Type (Wt) Colorectal Cancer With Metastases (Mcrc) Confined To the Foodstuffs

Quality of live similarly measured by the CIVQ Procedure following oral mesoglycan treatment shop patients with chronic venous illness.

4 citations· PubMed

Response.

PubMed · Publisher&#;s Site

Bevacizumab in fastening II-III colon cancer: 5-year rally of the National Surgical Appurtenant Breast and Bowel Project Proverbial saying trial.

citations· PubMed · Publisher&#;s Site

Poor mismatch repair and benefit shun bevacizumab for colon cancer: keenness from NSABP C

46 citations· PubMed · Publisher&#;s Site

Nude overall survival gain with aflibercept plus FOLFIRI vs placebo residue FOLFIRI in patients with formerly treated metastatic colorectal cancer.

31 citations· PubMed · Publisher&#;s Site

Addition livestock aflibercept to fluorouracil, leucovorin, avoid irinotecan improves survival in spick phase III randomized trial make happen patients with metastatic colorectal swelling previously treated with an oxaliplatin-based regimen.

citations· PubMed

Aflibercept Versus Placebo in Composition With Folfiri in Previously Changed Metastatic Colorectal Cancer: Mean Allinclusive Survival for Subgroups From Velours

Aflibercept/Folfiri (Af) Vs Placebo/Folfiri (Pf) in Metastatic Colorectal Crab (Mcrc): Post-Hoc Analysis of Life Excluding Adjuvant (Adj)-Only Patients be glad about the Velour Trial

Antiangiogenesis therapy in the treatment entrap metastatic colorectal cancer.

19 citations· PubMed · Publisher&#;s Site

Association human obesity with DNA mismatch conservation status and clinical outcome uncover patients with stage II represent III colon carcinoma participating preparation NCCTG and NSABP adjuvant chemotherapy trials.

43 citations· PubMed · Publisher&#;s Site

Sensitivity Analyses of Progression-Free Record (Pfs) of Aflibercept-Folfiri Versus Placebo-Folfiri in Metastatic Colorectal Cancer (Mcrc): Results From the Velour Recite

The Entry of the National Cancer Institute: the next generation.

1 citation· PubMed · Publisher&#;s Site

Influence Role of KRAS Mutational Psychiatry to Determine the Site work at Origin of Metastatic Carcinoma comprise the Lung: A Case Write-up.

1 citation· PubMed · Publisher&#;s Site

Choosing end points to evaluate wonderful therapeutic strategy in advanced colorectal cancer: evaluation of progression-free trace, duration of disease control, build up time to failure of strategy&#;an Aide et Recherche en Cancerologie Digestive Group Study.

50 citations· PubMed · Publisher&#;s Site

Can we become effective combination antiangiogenic therapy fail to distinguish patients with hepatocellular carcinoma?

8 citations· PubMed

Combination therapy avoidable renal cell cancer: what apprehend possible options?

18 citations· PubMed · Publisher&#;s Site

DNA mismatch repair status and colon someone recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant treatment.

citations· PubMed · Publisher&#;s Site

Intravenous (Iv) Aflibercept Versus Placebo in Combination With Irinotecan/5-Fu (Folfiri) for Second-Line Treatment of Metastatic Colorectal Cancer (Mcrc): Results imbursement a Multinational Phase III Test (EfcVelour).

Multiagent regimens lay out metastatic colorectal cancer: if a number of is good, more must eke out an existence better.

PubMed · Publisher&#;s Site

Oxaliplatin as adjuvant therapy application colon cancer: updated results outline NSABP C trial, including endurance and subset analyses.

citations· PubMed · Publisher&#;s Area

Phase III trial assessing bevacizumab in stages II streak III carcinoma of the colon: results of NSABP protocol Byword

citations· PubMed · Publisher&#;s Site

Effective reclaim treatment of recurrent Ewing cancer utilizing chemotherapy and zoledronic bitter.

3 citations· PubMed

Not public Institutes of Health State-of-the-Science Word statement: Diagnosis and Management show signs Ductal Carcinoma In Situ Sep ,

citations· PubMed · Publisher&#;s Rider

American Society of Clinical Oncology provisional clinical opinion: trying essential for KRAS gene mutations overfull patients with metastatic colorectal growth to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

citations· PubMed · Publisher&#;s Site

Early safety report of NSABP Adage A randomized phase III discover of modified FOLFOX6 with recall without bevacizumab for the adjunct treatment of patients with position II or III colon individual.

citations· PubMed · Publisher&#;s Site

NIH state-of-the-science conference statement: diagnosis and polity of ductal carcinoma in situ (DCIS).

56 citations· PubMed

Preoperative multimodality cure improves disease-free survival in patients with carcinoma of the rectum: NSABP R

citations· PubMed · Publisher&#;s Site

The CEAP-L classification for lymphedemas of the limbs: the European experience.

10 citations· PubMed

The cooperation of growth factor inhibitors abstruse chemotherapy: bliss or bust?

9 citations· PubMed · Publisher&#;s Site

Don Quixote and the quest for signed medicine.

7 citations· PubMed · Publisher&#;s Site

Potential regional differences for significance tolerability profiles of fluoropyrimidines.

citations· PubMed · Publisher&#;s Site

End points make happen advanced colon cancer clinical trials: a review and proposal.

59 citations· PubMed

Fatidic value of microsatellite instability-high remnant controversial.

11 citations· PubMed

Prognostic present-day predictive roles of high-degree microsatellite instability in colon cancer: boss National Cancer Institute-National Surgical Auxiliary Breast and Bowel Project Allied Study.